Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)

Autor: Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, Dimitri Pureur, François Ghiringhelli, Eric Assenat, Pascal Hammel, Olivier Rosmorduc, Morgane Stouvenot, Manon Allaire, Mohamed Bouattour, Hélène Regnault, Serge Fratte, Eric Raymond, Emilie Soularue, Stéphanie Husson-Wetzel, Vincent Di Martino, Allison Muller, Anne-Laure Clairet, Christine Fagnoni-Legat, Olivier Adotevi, Aurélia Meurisse, Dewi Vernerey, Christophe Borg

Publikováno v: BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)

Abstract Background Several cancer immunotherapies that target the PD-L1/PD-1 pathway show promising clinical activity in patients with hepatocellular carcinoma (HCC). However, the standard of care in first-line treatment with atezolizumab (anti-PD-L

Externí odkaz: https://doaj.org/article/39a0fdecdfae4b14bb524649b02db940

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

Autor: Magali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, Marion Jacquin, Francois Ghiringhelli, Christelle de la Fouchardière, Benoit You, Tristan Maurina, Elsa Kalbacher, Fernando Bazan, Guillaume Meynard, Anne-Laure Clairet, Christine Fagnoni-Legat, Laurie Spehner, Adeline Bouard, Dewi Vernerey, Aurélia Meurisse, Stefano Kim, Christophe Borg, Laura Mansi

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

BackgroundThere is a strong rational of using anti–programmed cell death protein-1 and its ligand (anti–PD-1/L1) antibodies in human papillomavirus (HPV)–induced cancers. However, anti–PD-1/L1 as monotherapy induces a limited number of object

Externí odkaz: https://doaj.org/article/90ac113021e14bb9a976565c61b79c86

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study

Autor: Olivier Adotévi, Dewi Vernerey, Pascale Jacoulet, Aurélia Meurisse, Caroline Laheurte, Hamadi Almotlak, Marion Jacquin, Vincent Kaulek, Laura Boullerot, Marine Malfroy, Emeline Orillard, Guillaume Eberst, Aurélie Lagrange, Laure Favier, Marie Gainet-Brun, Ludovic Doucet, Luis Teixeira, Zineb Ghrieb, Anne-Laure Clairet, Yves Guillaume, Marie Kroemer, Didier Hocquet, Mélanie Moltenis, Samuel Limat, Elisabeth Quoix, Céline Mascaux, Didier Debieuvre, Christine Fagnoni-Legat, Christophe Borg, Virginie Westeel

Publikováno v: Journal of Clinical Oncology. 41:373-384

PURPOSE Universal cancer peptide–based vaccine (UCPVax) is a therapeutic vaccine composed of two highly selected helper peptides to induce CD4+ T helper-1 response directed against telomerase. This phase Ib/IIa trial was designed to test the safety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d89a35baf49f743bcea131115f667da9
https://doi.org/10.1200/jco.22.00096

Enhanced emergence of antibiotic-resistant pathogenic bacteria after in vitro induction with cancer chemotherapy drugs

Autor: Marion Richard, Didier Hocquet, Didier Mazel, Christine Fagnoni-Legat, Virginie Nerich, Alexandre Meunier, Xavier Bertrand, Olivier Adotevi

Publikováno v: Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, 2019, 74 (6), pp.1572-1577. ⟨10.1093/jac/dkz070⟩
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2019, 74 (6), pp.1572-1577. ⟨10.1093/jac/dkz070⟩

International audience; BACKGROUND:Infections with antibiotic-resistant pathogens in cancer patients are a leading cause of mortality. Cancer patients are treated with compounds that can damage bacterial DNA, potentially triggering the SOS response,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba8fdee4c603dee85365989bf981a236
https://pubmed.ncbi.nlm.nih.gov/30789224

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82).

Autor: Vienot, Angélique^1,2,3,4 (AUTHOR) a3vienot@chu-besancon.fr, Jacquin, Marion^1,2 (AUTHOR), Rebucci-Peixoto, Magali^1,2 (AUTHOR), Pureur, Dimitri^1,5 (AUTHOR), Ghiringhelli, François⁶ (AUTHOR), Assenat, Eric⁷ (AUTHOR), Hammel, Pascal⁸ (AUTHOR), Rosmorduc, Olivier⁹ (AUTHOR), Stouvenot, Morgane^1,10 (AUTHOR), Allaire, Manon¹¹ (AUTHOR), Bouattour, Mohamed¹² (AUTHOR), Regnault, Hélène¹³ (AUTHOR), Fratte, Serge¹⁴ (AUTHOR), Raymond, Eric¹⁵ (AUTHOR), Soularue, Emilie¹⁶ (AUTHOR), Husson-Wetzel, Stéphanie¹⁷ (AUTHOR), Di Martino, Vincent⁵ (AUTHOR), Muller, Allison¹⁸ (AUTHOR), Clairet, Anne-Laure¹⁹ (AUTHOR), Fagnoni-Legat, Christine¹⁹ (AUTHOR)

Publikováno v: BMC Cancer. 7/29/2023, Vol. 23 Issue 1, p1-9. 9p.